Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hepatic Impairment
Interventions
Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Rialto, California • Orlando, Florida • San Antonio, Texas
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
7,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
133
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 112 more
Conditions
Cardiovascular Disease
Interventions
Olpasiran, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years to 105 Years
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
205
States / cities
Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 170 more
Conditions
Cardiovascular Disease
Interventions
Olpasiran, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Beverly Hills, California • Boca Raton, Florida • Atlanta, Georgia + 7 more
Conditions
Renal Impairment
Interventions
Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Rialto, California • Yucaipa, California • Miami, Florida + 2 more
Conditions
Cardiovascular Disease
Interventions
Olpasiran, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
35 Years to 80 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Bridgeport, Connecticut • Jacksonville, Florida • Overland Park, Kansas + 3 more